mRNA produced by VSW-3 RNAP has high-level translation efficiency with low inflammatory stimulation

Guoquan Wang , Rui Cheng , Qiubing Chen , Yuandong Xu , Bingbing Yu , Bin Zhu , Hao Yin , Heng Xia
{"title":"mRNA produced by VSW-3 RNAP has high-level translation efficiency with low inflammatory stimulation","authors":"Guoquan Wang ,&nbsp;Rui Cheng ,&nbsp;Qiubing Chen ,&nbsp;Yuandong Xu ,&nbsp;Bingbing Yu ,&nbsp;Bin Zhu ,&nbsp;Hao Yin ,&nbsp;Heng Xia","doi":"10.1016/j.cellin.2022.100056","DOIUrl":null,"url":null,"abstract":"<div><p><em>In vitro</em> preparation of mRNA is a key step for mRNA therapeutics. The widely used T7 RNA polymerase (RNAP) was shown to have many by-products during <em>in vitro</em> transcription (IVT) process, among which double-stranded RNA (dsRNA) is the major by-product to activate the intracellular immune response. Here, we describe the use of a new VSW-3 RNAP that reduced dsRNA production during IVT and the resulting mRNA exhibited low inflammatory stimulation in cells. Compared to T7 RNAP transcripts, these mRNA exhibited superior protein expression levels, with an average of 14-fold increase in Hela cells and 5-fold increase in mice. In addition, we found that VSW-3 RNAP did not require modified nucleotides to improve protein production of IVT products. Our data suggest that VSW-3 RNAP could be a useful tool for mRNA therapeutics.</p></div>","PeriodicalId":72541,"journal":{"name":"Cell insight","volume":"1 5","pages":"Article 100056"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/80/main.PMC10120321.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell insight","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772892722000530","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

In vitro preparation of mRNA is a key step for mRNA therapeutics. The widely used T7 RNA polymerase (RNAP) was shown to have many by-products during in vitro transcription (IVT) process, among which double-stranded RNA (dsRNA) is the major by-product to activate the intracellular immune response. Here, we describe the use of a new VSW-3 RNAP that reduced dsRNA production during IVT and the resulting mRNA exhibited low inflammatory stimulation in cells. Compared to T7 RNAP transcripts, these mRNA exhibited superior protein expression levels, with an average of 14-fold increase in Hela cells and 5-fold increase in mice. In addition, we found that VSW-3 RNAP did not require modified nucleotides to improve protein production of IVT products. Our data suggest that VSW-3 RNAP could be a useful tool for mRNA therapeutics.

Abstract Image

VSW-3 RNAP产生的mRNA具有高翻译效率和低炎症刺激
mRNA的体外制备是mRNA治疗的关键步骤。广泛使用的T7 RNA聚合酶(RNAP)在体外转录(IVT)过程中有许多副产物,其中双链RNA (dsRNA)是激活细胞内免疫反应的主要副产物。在这里,我们描述了一种新的VSW-3 RNAP的使用,该RNAP在IVT期间减少了dsRNA的产生,并且由此产生的mRNA在细胞中表现出低炎症刺激。与T7 RNAP转录本相比,这些mRNA表现出更高的蛋白表达水平,在Hela细胞中平均增加14倍,在小鼠中平均增加5倍。此外,我们发现VSW-3 RNAP不需要修饰核苷酸来提高IVT产物的蛋白质产量。我们的数据表明,VSW-3 RNAP可能是mRNA治疗的有用工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cell insight
Cell insight Neuroscience (General), Biochemistry, Genetics and Molecular Biology (General), Cancer Research, Cell Biology
CiteScore
2.70
自引率
0.00%
发文量
0
审稿时长
35 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信